Publicação: The use of heterocyclic-based azo compounds bearing pyrrolidine, imidazole, triazole, and thiazole moieties for the treatment of neglected tropical disease caused by Schistosoma mansoni
| dc.contributor.author | Scarim, Cauê Benito [UNESP] | |
| dc.contributor.author | Chin, Chung Man [UNESP] | |
| dc.contributor.institution | Universidade Estadual Paulista (UNESP) | |
| dc.contributor.institution | Lapdesf - Laboratory of Research and Development of Drugs | |
| dc.contributor.institution | Union of the Colleges of the Great Lakes (UNILAGO) | |
| dc.date.accessioned | 2023-07-29T15:34:47Z | |
| dc.date.available | 2023-07-29T15:34:47Z | |
| dc.date.issued | 2021-07-01 | |
| dc.description.abstract | Schistosomiasis (e.g. Schistosoma mansoni) is a neglected tropical disease caused by parasitic worms. It can advance from an acute (juvenile form) to chronic stage (adult form). Single-dose praziquantel (PZQ) is the only therapeutic drug option for adult schistosomiasis (SM) treatment, while its inability to efficiently inhibit earlier larval stages. Its use does not eliminate risks regarding the formation of resistant worms. Thus, new drug candidates to treat SM are urgently needed. Acting as molecule scaffolds, heterocyclic-based azo compounds have shown potential in the treatment of various diseases, including SM. This review article examines several medicinal chemistry-related studies involving these pharmacophore classes (pyrrolidine, imidazole, triazole, and thiazole) from 2011 to 2021, with a focus on SM. Our aim is to facilitate the drug design of novel molecules by optimizing anthelmintic conjugates. | en |
| dc.description.affiliation | Sao Paulo State University (UNESP) School of Pharmaceutical Sciences, SP | |
| dc.description.affiliation | Lapdesf - Laboratory of Research and Development of Drugs, SP | |
| dc.description.affiliation | School of Medicine Union of the Colleges of the Great Lakes (UNILAGO), SP | |
| dc.description.affiliationUnesp | Sao Paulo State University (UNESP) School of Pharmaceutical Sciences, SP | |
| dc.description.sponsorship | Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) | |
| dc.description.sponsorshipId | CAPES: 001 | |
| dc.identifier | http://dx.doi.org/10.1016/j.ejmcr.2021.100001 | |
| dc.identifier.citation | European Journal of Medicinal Chemistry Reports, v. 1. | |
| dc.identifier.doi | 10.1016/j.ejmcr.2021.100001 | |
| dc.identifier.issn | 2772-4174 | |
| dc.identifier.scopus | 2-s2.0-85143138741 | |
| dc.identifier.uri | http://hdl.handle.net/11449/249427 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | European Journal of Medicinal Chemistry Reports | |
| dc.source | Scopus | |
| dc.subject | New compounds | |
| dc.subject | Nitro-based compounds | |
| dc.subject | Schistosoma mansoni | |
| dc.subject | Schistosomiasis | |
| dc.title | The use of heterocyclic-based azo compounds bearing pyrrolidine, imidazole, triazole, and thiazole moieties for the treatment of neglected tropical disease caused by Schistosoma mansoni | en |
| dc.type | Resenha | pt |
| dspace.entity.type | Publication | |
| relation.isDepartmentOfPublication | e214da1b-9929-4ae9-b8fd-655e9bfeda4b | |
| relation.isDepartmentOfPublication.latestForDiscovery | e214da1b-9929-4ae9-b8fd-655e9bfeda4b | |
| unesp.department | Fármacos e Medicamentos - FCF | pt |